Comparing Empagliflozin vs Ozempic
| Empagliflozin | Ozempic (semaglutide) |
|
|---|
| Empagliflozin | Ozempic (semaglutide) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Kidney Disease, Heart Failure, Type 2 Diabetes, Cardiovascular Risk Reduction. Empagliflozin may also be used for purposes not listed in this medication guide. |
Prescription only
Ozempic lowers blood sugar levels by mimicking the effects of GLP-1, a naturally occurring hormone that stimulates insulin secretion and lowers glucagon secretion from the liver. It is... View more |
Related suggestions Type 2 Diabetes
Cardiovascular Risk Reduction
Chronic Kidney Disease
|
|||||||
| More about Empagliflozin | More about Ozempic (semaglutide) | ||||||||
| Ratings & Reviews | |||||||||
|
Empagliflozin has an average rating of 5.4 out of 10 from a total of 347 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 41% reported a negative effect. |
Ozempic has an average rating of 6.7 out of 10 from a total of 1560 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 23% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Empagliflozin side effects |
View all Ozempic side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ozempic prices |
||||||||
| Dosage Forms | |||||||||
|
N/A |
|
||||||||
| Brand Names | |||||||||
| Jardiance | Other semaglutide brands include: Rybelsus, Wegovy | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
12.4 hours |
168 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 431 drugs are known to interact with Empagliflozin:
|
A total of 273 drugs are known to interact with Ozempic:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
August 01, 2014 |
N/A |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Jardiance
Jardiance (empagliflozin) is used to treat type 2 diabetes, chronic kidney disease and reduce the ...
Farxiga
Farxiga (dapagliflozin) is an oral prescription medication that may be given to certain adults with ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Kerendia
Kerendia is used for the treatment of patients with chronic kidney disease (CKD) associated with ...
Dapagliflozin
Dapagliflozin (Farxiga) is an SGLT2 inhibitor that is mainly used alongside diet and exercise to ...
Semaglutide
Semaglutide is a GLP-1 agonist used for weight loss, type 2 diabetes, and reducing cardiovascular ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.